
Managing Male OAB: Update for the APP Webcast (2025)

The American Urological Association is proud to offer Managing Male OAB: Update for the Advanced Practice Provider, a dynamic educational activity, featuring a multidisciplinary panel of experts, including a nurse practitioner, physician assistant, and urologist, that will build upon the success of previous AUA education in OAB. Based on the documented educational need, the AUA will update APPs on the latest advancements in the management of patients with OAB, specifically OAB associated with Benign Prostatic Hyperplasia (BPH).
ACKNOWLEDGEMENTS
Support provided by an independent educational grant from:
- Sumitomo Pharma America, Inc.
Target Audience
- APPs
Learning Objectives
After participating in this CME activity, participants will be able to:
- Counsel and treat patients with OAB by incorporating current evidence on its epidemiology, burden and association of OAB in men with BPH.
- Integrate into practice the principles for diagnosis, counseling and treatment of OAB based on the clinical recommendations from the 2024 AUA/SUFU Guideline including the application of the Guideline to men with OAB associated with BPH.
- Implement OAB treatment strategies that incorporate evidence-based knowledge and patient centered considerations, including efficacy and side effects of treatment.
- Differentiate OAB medications based on mechanisms of action, side effects, and contraindications.
- Evaluate and apply emerging evidence of the association of antimuscarinic medications with cognitive decline, especially in the frail patients with OAB, into clinical decision making.
Welcome and Introductions
Segment 1: OAB in Men with BPH: Insights from the 2024 AUA/SUFU Guideline
Segment 2: Clinical Evaluation – Differentiating Voiding vs. Storage Symptoms
Segment 3: Management Pathway for Storage + Voiding Symptoms
Segment 4: Medication Strategy—Evidence, Comfort, and Combination Therapy
Segment 5: Advanced & Procedural Options
Wrap-up
| Name | Company Name | Relationship Type | End Date |
| Hughes, Corinna | No relevant financial relationships to disclose | ||
| Mogil, Adam G. | No relevant financial relationships to disclose | ||
| Nitti, Victor William | Bright Uro | Consultant or Advisor | Current |
| EG 427 | Consultant or Advisor | Current | |
| Abbvie | Consultant or Advisor | Current | |
EDUCATION COUNCIL DISCLOSURE
Education Council DTL 2025_1.pdf
COI REVIEW WORK GROUP DISCLOSURES
COI Review Workgroup DTL 2025_1.pdf
AUA Office of Education Staff has nothing to disclose.
All relevant financial relationships have been mitigated.
METHOD OF PARTICIPATION:
Learners will participate in this online educational activity by taking the pretest, viewing the webcast and completing the posttest and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.
Estimated time to complete this activity: 1.50 hours
Release Date: November, 2025
Expiration Date: November, 2026
ACCREDITATION:
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION:
The American Urological Association designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
OTHER LEARNERS:
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
EVIDENCE BASED CONTENT:
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA DISCLOSURE POLICY:
All persons in a position to control the content of a CME activity are required to disclose to the AUA, as the ACCME-accredited provider, all financial relationships with any ineligible company (formerly commercial interests) during the previous 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The AUA must determine if the individual’s relationships are relevant to the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners with information so they can make their own judgments.
MITIGATION OF IDENTIFIED CONFLICT OF INTEREST:
All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of relevant financial relationships that result in conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation.
AUA ACCREDITATION INFORMATION
OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:
The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
AUA PARTICIPANT INFORMATION & POLICIES
DISCLAIMER:
The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
REPRODUCTION PERMISSION:
Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.
Available Credit
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Non-Physician Participation

Facebook
X
LinkedIn
Forward